Here’s some news on the commercial front that shows stem cell therapy moving forward. The pharmaceutical giant Pfizer has made a teeny-tiny investment in stem cells, according to an article in Forbes.

Pfizer is financing a company called EyeCyte, which hopes to use cells from the blood and bone marrow to repair damaged blood vessels in the eyes of patients suffering from diabetes and macular degeneration. Pfizer spends over $8 billion in research and development and is investing $3 million in EyeCyte in exchange for having part ownership of the company and being its sole pharmaceutical partner. If the therapyworks, though, the payoff could be huge: biologics against macular degeneration have proved big business.